This protocol was written following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist (Additional file 1) [22]. The schedule of trial enrollment, interventions and assessments is presented in Table 1.
Table 1
Summarized study schedule at each visit in the clinical trial
|
STUDY PERIOD
|
|
Enrolment
|
Allocation
|
Post-allocation
|
TIME POINT
|
-t1
(2 weeks)
|
0
|
Visit 1
(4 weeks)
|
Visit 2
(8 weeks)
|
ENROLMENT
|
|
|
|
|
Eligibility screening
|
×
|
|
|
|
Informed consent
|
×
|
|
|
|
Allocation
|
|
×
|
|
|
INTERVENTIONS
|
|
|
|
|
Meal replacement group
|
|
|
×
|
×
|
No meal replacement group
|
|
|
×
|
×
|
ASSESSMENTS
|
|
|
|
|
FBG
|
|
×
|
|
×
|
Serum HbA1c
|
|
×
|
|
×
|
Lipid profile
|
|
×
|
|
×
|
Blood pressure
|
|
×
|
|
×
|
Anthropometric measures
|
|
×
|
×
|
×
|
Body composition measures
|
|
×
|
|
×
|
FFQ/ IPAQ
|
|
×
|
|
×
|
Objectives and hypothesis
Hypothesis:
Objectives:
-
Primary- to investigate if dinner meal replacement with a low calorie meal replacement shake is an effective strategy to achieve a minimum 5% body weight loss in shift workers with obesity compared to conventional dinner.
-
Secondary- to evaluate the effects on anthropometric parameters, serum lipids, glycemic outcomes and blood pressure.
Study design and setting
This study will be conducted as a parallel, randomized controlled clinical trial at the Nawaloka Hospital PLC, Colombo, Sri Lanka, for a period of 8 weeks, evaluating the effect of a meal replacement for dinner in obese shift workers.
Sample size
A sample of 44 healthcare employees who engage in shift work will be recruited for the study after screening for eligibility against inclusion and exclusion criteria mentioned below. The minimum sample size will be calculated based on the primary outcome, the proportion of participants achieving 5%weight loss after 8 weeks. Previous weight loss intervention trials predicted that 50% of individuals in the intervention group and 10% of participants in the control group would lose at least 5% of their baseline body weight after 8 weeks. [23]. To detect this difference in the proportion of participants achieving 5%weight loss between the intervention and control groups, 17 participants were required in each group, to ensure 80% power at a 5% significance level. To accommodate a 20% dropout rate,we therefore needed to recruit 22 participants in each intervention group. Hence, a total of 44 adults with obesity (BMI > 25kg/m2) will be recruited for the study [24]. The formula used for sample size calculation is presented below;

nB = Sample size in one arm
PA = Proportion of subjects expected to achieve 5% weight loss at the end of 8 weeks in placebo group (0.1)
PB = Proportion of subjects expected to achieve 5% weight loss at the end of 8 weeks in treatment group (0.5)
Κ = Sampling ratio (1:1)
Zα = Critical value of the normal distribution at α (α is 0.05 and the critical value is 1.96)
Zβ = Critical value of the normal distribution at β (β is 0.2)
Population
The study population will consist of obese health care employees in rotating shift work who provides health care services, either directly (e.g. Doctors and nurses) or indirectly (e.g. helpers, laboratory technicians, medical waste handlers, security officers).
Inclusion and exclusion criteria
Inclusion criteria
-
Permanent employees aged 18–65 years
-
Have been working shifts continuously for the past 12 months and continue during the whole study period (8 weeks).
-
Working at least 3 night shifts/week
-
Participants with BMI ≥ 25 kg/m2
-
Not having any allergies to any of the known food ingredients especially for milk and soya.
Exclusion criteria
-
Pregnant or lactating mothers
-
Having known chronic disease conditions
-
Having a known allergy history for milk or any of the ingredients in the meal replacement.
-
History of any type of minor or major surgical procedure in the past 6 months.
-
Currently on diet prescriptions or participating in regular physical activity sessions
Suspension criteria
-
Subject’s request to discontinue the study.
-
Serious adverse events or unusual changes in clinical test results.
-
Principal investigator’s decision to terminate the study (low compliance rate, complications or unable to continue the study due to various reasons).
Randomization
Participants satisfying the eligibility criteria will be allocated to control and intervention groups equally (1:1) using the simple random sampling technique. A computer-generated random numbers sequence would be used for randomization. Eligibility evaluation and enrolment will be conducted by one independent investigator, while randomization will be done by another investigator.
Interventions
The test group will be provided with a 200 kcal meal replacement shake consisting 20.0 g of protein, 4.5 g of fat, 18.2 g of carbohydrate and 3.6 g of fiber with other vitamins and minerals (supplementary table 1). The meal replacement will be in powdered form, and participants will be instructed to prepare the liquid shake by mixing 53 g of powdered meal replacement with 400 mL of water. They will be asked to consume one serving of the meal replacement shake to replace dinner for 5 days of the week for a period of 8 weeks. The intervention group will be given sufficient meal replacement tins with a label indicating the ingredients and the preparation method. Participants will be instructed not to consume any additional food in between dinner in the evening, and breakfast the following morning. The breakfast and lunch meals will be recommended as normal meals (the meals that they habitually eat).
The control group will be asked to continue their usual dinner meals during the study period. In addition, both the groups will be given general dietary and lifestyle advice through distribution of leaflets which includes basic dietary advice according to Sri Lankan food based dietary guidelines. Both groups will be advised to continue their habitual physical activities.
Study groups
The treatment group will receive the meal replacement shake for their dinner. The control group will be advised to continue their routine dinner.
Study period
The study lasts for 8 weeks, and periodic measurements will take place at: screening (visit 0), 4 weeks (visit 1), 8 weeks (visit 2) (see Fig. 1).
Primary outcome
The primary outcome will be body weight loss, and the proportion of participants that had a 5% body weight loss from baseline
Secondary outcomes
-
Changes in waist circumference, hip circumference, percentage body fat and fat free mass.
-
Change in systolic blood pressure and diastolic blood pressure.
-
Change in lipid profile from baseline - total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides.
-
Changes in glycemic control measures from baseline- fasting blood sugar, glycated haemoglobin (HbA1c).
Procedures
Recruitment
Healthcare employees of the Nawaloka Hospitals PLC, Colombo, Sri Lanka will be recruited on a voluntary basis for this study by advertising through notices and distribution of leaflets with study information. Informed written consent will be obtained from all study participants before recruitment.
Study schedule
Anthropometric measure, blood pressure, fasting plasma glucose, serum HbA1c and lipid profile will be measured at the time of recruitment of participants and will be repeated at the end of 8th week. However, anthropometry measures which will be again measured at the end of 4th week additionally. The details of items which will be measured at every visit are described in Table 1.
Measurement tools
Anthropometric measurements
Anthropometric measurements will be performed using calibrated equipment by trained personnel adhering to international recommendations. Height will be taken to the nearest 0.1 cm, as the maximum distance to the uppermost position on the head from heels, with the individual standing barefoot and in full inspiration using a calibrated stadiometer (Seca 213 portable stadiometer). Body weight will be measured to the nearest 0.1 kg using a calibrated digital weighing scale (Seca 813, Hamburg, Germany) with the participants wearing indoor light clothing and after emptying the bladder. Waist circumference will be measured midway between the iliac crest and the lower rib margin at the end of normal expiration using a plastic flexible tape to the nearest 0 .1 cm. Similarly, the hip circumference will be measured at the widest level over the greater trochanters level to the nearest 0 .1 cm. BMI will be calculated as body mass in kilograms divided by height in meters squared (kg/m2) and waist-to-hip ratio by dividing measured waist by hip circumference.
Body composition
Resistance (R) and reactance (X) will be assessed by bio-electrical impedance analysis (BIA) using a commercial portable device (Bodystat 1500, Bodystat Ltd, Isle of Man, British Isles) with hand-to-foot single frequency measurement while the subject remained supine. The participants will be asked to lie in supine position, and then the electrodes of the BIA device will be placed on the right hand and foot. Metal objects will be removed from the body, and measurements will be taken at room temperature. To calculate fat free mass and BF%, the resistance and reactance values will be applied to an ethnic-specific prediction equation developed for Asians [25].
Dietary measurements
A culturally validated Food Frequency Questionnaire (FFQ) will be used to obtain habitual intake of calories, macronutrients and micronutrients [26]. The energy content of each food component will be calculated using standard energy values for the portion sizes. The daily energy intakes are to be calculated using Nutri-Survey Software (EBISpro) modified with Sri Lankan food composition data.
Physical activity
Physical activity will be evaluated using the International Physical Activity Questionnaire (IPAQ) short version [27].
Biochemical analysis
A venous blood sample of 10–12 mL will be collected from each participant after an overnight fasting. Blood glucose, total cholesterol, triglycerides, and HDL-cholesterol will be determined using a Cobas c501 auto analyzer using an electrochemiluminescent immunoassay (ECLIA, Roche Diagnostics). LDL-cholesterol will be determined using the Friedewald formula. HbA1c will be evaluated by ion-exchange high-performance liquid chromatography.
Clinical examination
Seated blood pressure will be recorded to on two occasions after at least a 10-min rest using a digital blood pressure monitors (Omron Healthcare, Singapore).
Compliance calculation
Powdered meal replacement will be dispensed to each participant at baseline, end of the 2nd, 4th and 6th weeks. Participants will be instructed to return any unused meal replacement powder to the investigator at the end of the study. Compliance will be evaluated using the following formula:
Compliance % =\(\frac{\left(Distributed mealreplacement quantity–Remaining mealreplacement quantity\right)}{Distributed mealreplacement quantity}\times 100\)
In addition, researchers will phone participants periodically to monitor the consumption of the meal replacement. Each participant will be asked to record the meal replacement intake on each day in a compliance assessment sheet provided at baseline. At each visit these consumption records will be cross-checked with subjects. WhatsApp® groups will be created for communication with intervention and control groups.
Statistical analysis
Using SPSS version 23 (SPSS Inc., Chicago, IL, USA), parametric and non-parametric statistical tests will be applied for data analysis. Summary statistics of each group will be computed and presented as mean, standard deviation and proportion. Using a paired t-test, the baseline and end of study characteristics as well as the laboratory results of the groups will be compared and a P value of < 0.05 will be considered significant. Multiple regression analysis will be used to assess other factors influencing the weight change. Distributions of continuous variables will be tested for normality using the Kolmogorov-Smirnov test. The non-parametric Mann-Whitney U test will be used for asymmetrical continuous variables.
Adverse effect evaluation
The meal replacement provides one-third of the Recommended Daily Allowance (RDA) of micro nutrients in addition to 20 g of protein and sufficient amount of fiber. Therefore, micronutrient deficiencies are very unlikely to occur. Furthermore, all participants will be thoroughly screened for any history of allergic reactions, particularly to milk products and other ingredients in the product. However, in the event of a probable adverse reaction the following precautions would ensure timely identification and management of patients:
-
Reporting—to monitor any potential adverse events, participants will have the opportunity to contact the researchers via WhatsApp®, 24hr daily.
-
During follow-up visits, adverse events will be noted by history and examination and investigated in detail. All adverse effects observed will be documented in the case report form.
-
Management—in the event of an adverse reaction requiring in-hospital management, the facilities and expert management would be available at the Nawaloka Hospital PLC, Colombo, Sri Lanka.
-
Termination of study—the complete clinical trial will be terminated prematurely if there is evidence that the safety of the trial participants can no longer be guaranteed, or new scientific information arises during course of the clinical trial regarding safety of the patients.
Data collection
Data collection will be performed according to the standard operating procedures (SOPs) by the principal investigator and trained research assistants.
Data management and monitoring
Storage: Data and documents will be locked and secured for 5 years, under the supervision of the principal investigator. Simultaneously, electronic copies will be stored in the Queensland University of Technology (QUT) Research Data Storage Service according to the QUT data management plan for the above prescribed period. Data will be entered by a minimum number of dedicated staff and saved in a dedicated computer with password protection. Samples will be stored in a secure facility, with measures taken to ensure that specimens are kept under correct and constant conditions at all times when in storage. Expert staff that are trained specifically in sample storage and transportation would ensure that all regulatory issues are properly handled.
Dissemination of study finding
The results of the above study will be disseminated as publications and presentations in national and international journals or scientific meetings.
Ethical considerations
The study protocol has been reviewed and approved by the Queensland University of Technology, Human Research Ethics Committee (UHREC approval no: 4878) and the institutional approval to conduct the study was taken from the Nawaloka Hospitals Research and Education Foundation, Colombo, Sri Lanka. The trial is also registered at the Australian New Zealand Clinical Trials Registry (ACTRN12622000231741). The study will be conducted in compliance with the Declaration of Helsinki and the good clinical practice guidelines. Any change in trial protocol will be notified to the relevant regulatory authorities and trial participants, with re-consent being taken from participants, if required.